Ironwood Pharmaceuticals (IRWD) Other Non-Current Liabilities (2011 - 2026)

Ironwood Pharmaceuticals has disclosed Other Non-Current Liabilities across 15 years of filings, most recently posting $20.5 million for Q2 2026.

• In Q2 2026, Other Non-Current Liabilities fell 8.59% year-over-year to $20.5 million; the TTM figure through Jun 2026 stood at $20.5 million (down 8.59% YoY), while the FY2025 annual figure was $21.6 million, up 26.56% from the prior year.
• Other Non-Current Liabilities came in at $20.5 million for Q2 2026 at Ironwood Pharmaceuticals, down from $21.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $39.8 million in Q3 2024 to a low of $5.1 million in Q1 2022.
• Average Other Non-Current Liabilities over 5 years is $21.1 million, with a median of $21.4 million recorded in 2025.
• Year-over-year, Other Non-Current Liabilities surged 478.86% in 2022 and plunged 44.14% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $9.8 million in 2022, then jumped by 190.96% to $28.4 million in 2023, then tumbled by 39.8% to $17.1 million in 2024, then increased by 26.56% to $21.6 million in 2025, then retreated by 5.14% to $20.5 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $20.5 million in Q2 2026, $21.2 million in Q1 2026, and $21.6 million in Q4 2025.